AstraZeneca partners with insitro in a deal worth up to $1.5 billion to use Virtual Human AI for discovering potential treatments for liver and heart diseases.
AstraZeneca partners with insitro in a deal worth up to $1.5 billion to use Virtual Human AI for discovering potential treatments for liver and heart diseases.